|
|
Matrix-S |
|
Vaxjo ID |
106 |
|
Vaccine Adjuvant Name |
Matrix-S |
|
Adjuvant VO ID |
VO_0001324
|
|
Stage of Development |
Research |
|
Function |
This adjuvant activates the NLRP3 inflammasome and creates a slow-release depot for antigen, while potently recruiting leukocytes—including T cells, B cells, NK cells, and dendritic cells—into draining lymph nodes. Its pleiotropic actions enhance both humoral and cellular immunity, resulting in robust, broad immune responses. |
| Related Vaccine(s) |
|
| References |
Alturki et al., 2020: Alturki SO, Alturki SO, Connors J, Cusimano G, Kutzler MA, Izmirly AM, Haddad EK. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development. Frontiers in immunology. 2020; 11; 1880. [PubMed: 32973779].
Flock et al., 2006: Flock M, Karlström A, Lannergård J, Guss B, Flock JI. Protective effect of vaccination with recombinant proteins from Streptococcus equi subspecies equi in a strangles model in the mouse. Vaccine. 2006; 24(19); 4144-4151. [PubMed: 16580099].
Rezaei and Nazari, 2022: Rezaei M, Nazari M. New Generation Vaccines for COVID-19 Based on Peptide, Viral Vector, Artificial Antigen Presenting Cell, DNA or mRNA. Avicenna journal of medical biotechnology. 2022; 14(1); 30-36. [PubMed: 35509358].
|
|
